Valérie Cuvier
Publications by Year
Research Areas
Inflammation biomarkers and pathways, Sepsis Diagnosis and Treatment, Intensive Care Unit Cognitive Disorders, Neurogenetic and Muscular Disorders Research, Amyotrophic Lateral Sclerosis Research
Most-Cited Works
- → Effect of intravenous TRO40303 as an adjunct to primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: MITOCARE study results(2014)185 cited
- → A phase II−III trial of olesoxime in subjects with amyotrophic lateral sclerosis(2014)127 cited
- → Nangibotide in patients with septic shock: a Phase 2a randomized controlled clinical trial(2020)70 cited
- → Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trial(2023)65 cited
- → A first‐in‐man safety and pharmacokinetics study of nangibotide, a new modulator of innate immune response through TREM‐1 receptor inhibition(2018)44 cited
- → Rationale and protocol for the efficacy, safety and tolerability of nangibotide in patients with septic shock (ASTONISH) phase IIb randomised controlled trial(2021)20 cited
- → Evaluation of the efficacy and safety of TREM-1 inhibition with nangibotide in patients with COVID-19 receiving respiratory support: the ESSENTIAL randomised, double-blind trial(2023)16 cited
- → Results of a Phase 1b study to confirm safety and tolerability of olesoxime in multiple sclerosis patients (P7.282)(2015)9 cited
- → Results of a Phase II Study to Assess Safety and Efficacy of Olesoxime (TRO19622) in 3- to 25-Year-Old Spinal Muscular Atrophy Patients(2014)8 cited
- → G.O.19(2014)4 cited